Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4062 ARTÍCULOS , VIENDO DEL 811 AL 825

Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy

Stamelou M, Schöpe J, Wagenpfeil S, Del Ser T, Bang J, Lobach IY, Luong P, Respondek G, Oertel WH, Boxer A, Höglinger GU; AL-108-231 Investigators, Tauros Investigators, and MDS-Endorsed PSP Study Group.

Mov Disord. 2016 May;31(5):742-7. doi: 10.1002/mds.26580. Epub 2016 Mar 7.

Up-regulation of SNCA gene expression: implications to synucleinopathies

Tagliafierro L, Chiba-Falek O.

Neurogenetics. 2016 Jul;17(3):145-57. doi: 10.1007/s10048-016-0478-0. Epub 2016 Mar 7.

Psychosis in Parkinson's disease: unexplained observations in a seemingly simple model

Friedman JH, Akbar U.

Expert Rev Neurother. 2016 Jun;16(6):595-6. doi: 10.1586/14737175.2016.1162713. Epub 2016 Mar 30.

Clinical drug research in chronic central neurodegenerative disorders

Müller T, Foley P.

Expert Rev Neurother. 2016 May;16(5):497-504. doi: 10.1586/14737175.2016.1163220. Epub 2016 Mar 21.

Editorial: Critical Analyses of Mechanism-Based Therapies Against Parkinson's Disease: Concepts and Perspectives

Bisaglia M.

Curr Neuropharmacol. 2016;14(3):212-3. doi: 10.2174/1570159x1403160303151355.

Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension

Elgebaly A, Abdelazeim B, Mattar O, Gadelkarim M, Salah R, Negida A.

Clin Auton Res. 2016 Jun;26(3):171-80. doi: 10.1007/s10286-016-0349-7. Epub 2016 Mar 7.

Impact of Plant-Derived Flavonoids on Neurodegenerative Diseases

Costa SL, Silva VD, Dos Santos Souza C, Santos CC, Paris I, Muñoz P, Segura-Aguilar J.

Neurotox Res. 2016 Jul;30(1):41-52. doi: 10.1007/s12640-016-9600-1. Epub 2016 Mar 7.

Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects

Mestre TA, Lang AE, Okun MS.

Mov Disord. 2016 Mar;31(3):290-6. doi: 10.1002/mds.26500.

Continuous leg dyskinesia assessment in Parkinson's disease -clinical validity and ecological effect

Ramsperger R, Meckler S, Heger T, van Uem J, Hucker S, Braatz U, Graessner H, Berg D, Manoli Y, Serrano JA, Ferreira JJ, Hobert MA, Maetzler W; SENSE-PARK study team.

Parkinsonism Relat Disord. 2016 May;26:41-6. doi: 10.1016/j.parkreldis.2016.02.007. Epub 2016 Feb 10.

What can rodent models tell us about apathy and associated neuropsychiatric symptoms in Parkinson's disease?

Magnard R, Vachez Y, Carcenac C, Krack P, David O, Savasta M, Boulet S, Carnicella S.

Transl Psychiatry. 2016 Mar 8;6(3):e753. doi: 10.1038/tp.2016.17.

The Unbiased Search of Biomarkers in Neurodegenerative Diseases

Ferrara P.

Curr Pharm Biotechnol. 2016;17(5):471-9. doi: 10.2174/138920101705160303165719.

Glycosylation and other PTMs alterations in neurodegenerative diseases: Current status and future role in neurotrauma

Abou-Abbass H, Abou-El-Hassan H, Bahmad H, Zibara K, Zebian A, Youssef R, Ismail J, Zhu R, Zhou S, Dong X, Nasser M, Bahmad M, Darwish H, Mechref Y, Kobeissy F.

Electrophoresis. 2016 Jun;37(11):1549-61. doi: 10.1002/elps.201500585. Epub 2016 Apr 4.

Aging of perennial cells and organ parts according to the programmed aging paradigm

Libertini G, Ferrara N.

Age (Dordr). 2016 Apr;38(2):35. doi: 10.1007/s11357-016-9895-0. Epub 2016 Mar 8.

Oncostatic-Cytoprotective Effect of Melatonin and Other Bioactive Molecules: A Common Target in Mitochondrial Respiration

Pacini N, Borziani F.

Int J Mol Sci. 2016 Mar 7;17(3):341. doi: 10.3390/ijms17030341.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias